tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Hoth Therapeutics extending Phase II trial of HT-001 in cancer patients to EU

Hoth Therapeutics (HOTH) announced its engagement with ICON Clinical Research to expand its Phase II Clinical Trial for cancer patients suffering from skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors. Additional regulatory approval for the Phase II clinical trial is expected from potentially three EU countries in the upcoming months. The EU approval is part of the company’s international clinical development strategy for HT-001. The trial is currently enrolling patients in the U.S. This Phase 2a dose- ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1